Insider Selling: Cerus (NASDAQ:CERS) Insider Sells 101,740 Shares of Stock

March 17, 2026 by InsiderTrades.com

Key Points

CEO William Mariner Greenman sold 447,757 shares on March 12 at an average price of $1.66 for $743,276.62, reducing his stake by 8.22% to 4,998,493 shares (≈$8.30M).
Multiple other insiders also sold large blocks (including the CFO and incoming CEO Vivek Jayaraman), a pattern of insider liquidations that could increase short‑term investor concern about sentiment or liquidity needs.
Cerus announced a planned CEO succession: COO Vivek Jayaraman will become President and CEO effective July 1, 2026, with Greenman shifting to Executive Chairman — a pre‑announced move typically seen as a stabilizing governance signal.

Cerus Corporation (NASDAQ:CERS - Get Free Report) insider Richard Benjamin sold 101,740 shares of the company's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $1.66, for a total value of $168,888.40. Following the transaction, the insider directly owned 777,361 shares of the company's stock, valued at $1,290,419.26. This represents a 11.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Cerus Stock Up 6.5%

Shares of Cerus stock opened at $1.80 on Tuesday. The business's 50 day simple moving average is $2.28 and its 200 day simple moving average is $1.87. Cerus Corporation has a 52-week low of $1.12 and a 52-week high of $2.96. The firm has a market cap of $345.91 million, a PE ratio of -22.50 and a beta of 1.51. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.17 and a current ratio of 1.73.

Cerus (NASDAQ:CERS - Get Free Report) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.01). The firm had revenue of $64.58 million during the quarter, compared to the consensus estimate of $59.31 million. Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%. On average, analysts predict that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.

Cerus News Roundup

Here are the key news stories impacting Cerus this week:

Positive Sentiment: Cerus announced that COO Vivek Jayaraman will be promoted to President and Chief Executive Officer effective July 1, 2026, and current CEO William “Obi” Greenman will become Executive Chairman; Jayaraman will join the board — a clear, pre-announced succession plan that investors typically view as a stabilizing, positive governance signal. Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
Neutral Sentiment: Related release and commentary also referenced executive compensation adjustments tied to the leadership change; depending on details (timing, equity grants, vesting), these can be viewed as neutral to slightly positive if they align management incentives with shareholders. Cerus Announces CEO Succession and Executive Compensation Changes
Negative Sentiment: CEO William Mariner Greenman sold 447,757 shares at an average price of $1.66 (an ~8.22% reduction in his holding), a sizable insider sale that can spook investors even though he remains a large shareholder. SEC Filing
Negative Sentiment: CFO Kevin Dennis Green sold 127,544 shares at $1.66 (a ~10.92% reduction), another material insider liquidation that may raise short‑term concern about insider sentiment or liquidity needs. SEC Filing
Negative Sentiment: COO Vivek K. Jayaraman (the incoming CEO) sold 165,200 shares at $1.66 (~8.64% reduction); insider sales by the incoming CEO can create mixed signals despite the succession announcement. SEC Filing
Negative Sentiment: Other insiders (Richard J. Benjamin and Chrystal Jensen) also sold large blocks (~101,740 and 113,008 shares, respectively) at $1.66, further increasing selling pressure and potential investor concern about insider liquidity. Benjamin SEC Filing Jensen SEC Filing

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CERS. AQR Capital Management LLC raised its stake in shares of Cerus by 291.6% during the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company's stock worth $1,986,000 after purchasing an additional 1,064,133 shares in the last quarter. Kotler Kevin bought a new position in shares of Cerus in the fourth quarter valued at $2,084,000. UBS Group AG grew its stake in shares of Cerus by 227.1% in the fourth quarter. UBS Group AG now owns 1,142,502 shares of the biotechnology company's stock valued at $2,354,000 after buying an additional 793,244 shares in the last quarter. Globeflex Capital L P acquired a new position in Cerus during the fourth quarter worth $1,076,000. Finally, Millennium Management LLC increased its holdings in Cerus by 17.6% during the third quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company's stock worth $5,517,000 after buying an additional 519,301 shares during the last quarter. Institutional investors and hedge funds own 78.37% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on CERS. Wall Street Zen cut shares of Cerus from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. TD Cowen reissued a "buy" rating on shares of Cerus in a research report on Monday, January 12th. Finally, Zacks Research downgraded shares of Cerus from a "hold" rating to a "strong sell" rating in a research note on Thursday, March 12th. One equities research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Reduce".

Get Our Latest Stock Report on CERS

About Cerus

(Get Free Report)

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.